EGFR and non-small cell lung carcinoma: Encouragingly, co-administration of the EGFR inhibitor erlotinib with the AXL inhibitor SGI-7079 enhanced the sensitivity of mesenchymal-like NSCLC cells to erlotinib in an NSCLC mouse xenograft model, as detailed in Table 2 [218].